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Summary Infliximab is an anti-tumor necrosis factor-α 
monoclonal antibody shown to be effective in the treatment of 
moderate-to-severe psoriasis and psoriatic arthritis. We report on 
the first two patients in Croatia in which the efficacy of infliximab 
therapy was monitored and evaluated primarily on the basis of 
cutaneous manifestations of psoriasis. Both patients had severe, 
treatment-resistant chronic plaque psoriasis and psoriatic 
arthritis and were on methotrexate therapy before the initiation 
and throughout the course of infliximab treatment. Infliximab was 
administered intravenously at a dose of 4 or 5 mg/kg at week 
0, 2, 6 and every 8 weeks thereafter. Disease severity was 
measured before each infusion by means of Psoriasis Area and 
Severity Index (PASI) score. A remarkable clinical response was 
achieved in both patients with a 50% or greater improvement in 
baseline PASI at week 2 after therapy initiation and a 90% or 
greater improvement at week 6 in one patient and at week 14 
in the other. Both patients also reported a significant decline in 
their arthritis symptoms shortly after the introduction of infliximab. 
The concomitant use of infliximab and methotrexate in these two 
patients resulted in rapid and sustained remission of psoriasis 
with no major adverse effects detected. 
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INTroduCTIoN
 Psoriasis is a chronic, immune-mediated, in-
flammatory disease with predominantly skin and 
joint manifestations that can significantly affect the 
patients’ quality of life (1-3). A subset of patients 
with severe psoriasis remain poorly responsive 
to conventional therapies with narrow-band UVB 
and PUVA phototherapy, oral retinoids and immu-
nosuppressive drugs such as methotrexate and 
cyclosporine. According to the immune basis of 
psoriasis, biologic agents including T cell inhibi-
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tors and tumor necrosis factor (TNF)-α inhibitors 
have recently emerged as a new line of therapy 
for this disease (1,2). Many of these agents have 
been widely approved by the regulatory agencies 
for the treatment of moderate-to-severe psoriasis 
and psoriatic arthritis. In Croatia, the use of bio-
logic agents in the management of psoriasis is still 
restricted to patients with severe psoriatic arthritis 
resistant to disease-modifying antirheumatic drugs 
such as methotrexate. We report on the first two 
patients in our country treated and monitored for 
the efficacy of infliximab therapy at a dermatology-
venereology clinic, based primarily on the severity 
of cutaneous manifestations of psoriasis. 
 Infliximab (Remicade®), a TNF-α inhibitor, was 
administered intravenously over a period of 2.5 
hours at weeks 0, 2, and 6 and every 8 weeks 
thereafter according to the protocol for psoriasis 
and psoriatic arthritis (4-6). Before therapy initia-
tion, QuantiFERON-TB Gold and chest x-ray tests 
were performed in both patients to exclude latent 
tuberculosis, one of the absolute contraindications 
for the use of TNF-α inhibitors (1). Before each 
infusion, complete blood cell count, platelet count, 
basic biochemistry tests with liver enzymes, uri-
nalysis, erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP) levels were obtained. 
Patients were premedicated with dexamethasone 
to minimize the possibility for the occurrence of in-
fusion reactions, and were monitored for another 
2 hours after infusion. Disease severity was evalu-
ated before each infusion by means of Psoriasis 
Area and Severity Index (PASI) score. 
CaSe rePorTS
 Case 1
 A 64-year-old woman with a 20-year history of 
chronic plaque psoriasis had in the past received 
systemic therapy with acitretin, methotrexate as 
well as courses of PUVA and narrow-band UVB 
phototherapy, which all resulted in poor control of 
the disease. In the last 4 years, she developed 
symptoms of symmetric peripheral polyarthritis, 
seronegative for rheumatoid factor, when non-ste-
roidal anti-inflammatory drugs and occasional low 
dose steroids were introduced in therapy. Before 
the first infusion of infliximab, the patient had a 
PASI score of 28.2, pain and limitation of motion 
in knees, ankles and shoulders as well as painful 
swelling of distal interphalangeal joints. CRP level 
was increased to 50.3 mg/dL. She was on concur-
rent therapy with methotrexate (12.5 mg weekly 
dose with folate supplementation), ibuprofen and 
topical steroids. After the introduction of infliximab 
(5 mg/kg), the patient’s PASI score decreased to 
14 by week 2 (Fig. 1A, B) and to 11.6 by week 6. 
It was accompanied by considerable relief of joint 
pains and a decline in CRP level (14.4 and 4.6 
mg/dL, respectively). On day 5 of the first infusion, 
the patient became febrile up to 38 ˚C. Antibiot-
ic treatment was prescribed for a presumed uri-
nary tract infection and the patient turned afebrile 
within the next 4 days, so the second infusion of 
infliximab was not delayed. Fourteen weeks from 
the initiation of treatment, after having received 
3 infusions of infliximab, the patient’s skin mani-
festations improved by 90% from baseline, with a 
PASI score of 2.7 (Fig.1C). Unexpectedly, the pa-
tient complained of aggravation of joint symptoms 
characterized by pain in shoulders and knees that 
started 2 weeks prior to the scheduled fourth infu-
sion. This relapse of arthritis was accompanied by 
elevation in the ESR and CRP values (56 mm/h 
and 36.3 mg/dL, respectively), but responded well 
to subsequent therapy. Up to now, the patient has 
received 6 doses of infliximab and her skin re-
mained minimally affected by psoriatic lesions for 
Figure 1. Patient 1: front view of the trunk at baseline (A), after 2 weeks (B), 14 weeks (C) and 30 weeks 
(D) of treatment with infliximab (5 mg/kg). 
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30 weeks of the initiation of treatment (Fig. 1D). 
Her articular symptoms were also reduced signifi-
cantly, although she occasionally complained of 
pain in the involved joints. Treatment with inflix-
imab was well tolerated without any serious side 
effects detected. 
 Case 2
 A 27-year-old man with a 12-year history of 
chronic plaque psoriasis and psoriatic arthritis 
had frequent exacerbations of psoriasis involv-
ing more than 50% of total body surface area and 
was refractory to previous treatments with PUVA 
and narrow-band UVB phototherapy, acitretin and 
methotrexate. At the time of infliximab introduc-
tion, the patient was on therapy with narrow-band 
UVB, methotrexate (12.5 mg weekly dose with fo-
late supplementation) and diclofenac for his joint 
symptoms. The patient’s baseline PASI score was 
50.9 with involvement of more than 90% of total 
body surface area, he had generalized lymphade-
nopathy and difficulty in walking due to symmetric 
polyarthritis and spondylitis. Both the skin and joint 
manifestations of the disease responded dramati-
cally to the first infusion of infliximab (4 mg/kg). 
The patient experienced an instantaneous relief of 
his joint pains within the first 24 hours and had no 
need for treatment with diclofenac thereafter. His 
PASI score dropped to 24.8 by week 2 (Fig. 2A, 
B). The rapid clinical response to the infliximab 
treatment was further characterized by remark-
able reduction in ESR (from 74 to 20 mm/h) and 
CRP values (from 40.0 to 0.4 mg/dL). By week 
6 of the initiation of treatment, an impressive, 
95% improvement with a PASI score of 2.7 was 
achieved (Fig. 2C). ESR reduced to 8 mm/h and 
CRP remained low at 0.4 mg/dL. The beneficial 
effects of treatment were maintained by week 14, 
with complete clearance of psoriatic lesions (Fig. 
2D). Throughout the period of the first 4 infusions 
of infliximab, the patient did not experience any in-
fusion reaction or adverse effect of the treatment.
dISCuSSIoN
 According to the current concepts of pathogen-
esis, psoriasis is a T lymphocyte mediated auto-
immune disease (2). Recently developed biologic 
therapies approved for the management of moder-
ate-to-severe psoriasis specifically target T cells or 
inflammatory mediators. TNF-α is one of the cen-
tral cytokines involved in the molecular pathways 
of inflammation in psoriasis and its levels correlate 
with disease severity (2,7,8). Infliximab is a chime-
ric human-mouse monoclonal antibody that binds 
Figure 2. Patient 2: back view of the trunk and 
arms at baseline (A), after 2 weeks (B), 6 weeks 
(C) and 14 weeks (D) of treatment with infliximab 
(4 mg/kg).
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both to the soluble and the membrane-bound 
TNF-α, neutralizing its biologic activity (1,4). The 
efficacy of infliximab in the management of moder-
ate-to-severe chronic plaque psoriasis has already 
been established in clinical trials (5,6,9,10). More 
recent studies report on the efficacy and safety of 
infliximab in severe, treatment-resistant disease, 
or in combination with other immunosuppressant 
agents (11-14). 
 In our initial experience, based on the cases 
presented in this report, the concomitant use of 
infliximab and methotrexate can result in rapid 
and impressive improvement even in patients with 
severe, treatment-resistant psoriasis. The remark-
able clinical response observed in our patients is 
comparable with short-term response demonstrat-
ed by clinical trials (6,11-13). In a phase III trial of 
infliximab, at week 10 of infliximab monotherapy 
for moderate-to-severe psoriasis, 80% of patients 
achieved at least a 75% improvement from base-
line PASI score (PASI 75), and 57% of patients 
achieved at least a 90% improvement (PASI 90) 
(6). In a study that included patients on concomi-
tant therapy with infliximab and methotrexate for 
severe recalcitrant psoriasis, slightly lower PASI 
75 and PASI 90 rates at week 14 (68% and 52% 
of patients, respectively) have been reported (13). 
Both of our patients achieved 50% improvement in 
PASI score already by week 2, and PASI 90 was 
reached by week 6 and 14, respectively. A strik-
ing clinical response was observed in Patient 2, 
treated with a lower dose of infliximab (4 mg/kg), 
who reached practically complete remission of the 
disease with a 95% improvement in PASI already 
by week 6. The partial recurrence of joint symp-
toms in Patient 1 was probably a sign of different 
levels of infliximab efficacy achieved in joints and 
skin, implying differences in tissue-specific regula-
tion of inflammatory response. 
 During the infliximab maintenance therapy, 
loss of efficacy may occur due to the formation 
of neutralizing antibodies to infliximab (ATI). The 
development of ATI is also associated with an in-
creased risk of infusion reactions. However, it has 
been shown that low-dose methotrexate or other 
immunosuppressive treatment used concurrently 
with infliximab helps maintain clinical efficacy (15), 
while steroid premedication reduces the titer of ATI 
(15,16). Our patients were concomitantly treated 
with methotrexate (12.5 mg/kg weekly) and pre-
medicated with dexamethasone before each in-
fusion of infliximab. The beneficial effects of inf-
liximab therapy were sustained in both patients 
throughout the period of treatment (for 30 weeks 
in Patient 1 and for 14 weeks in Patient 2), and 
no infusion reaction was detected. Although inf-
liximab was generally well tolerated, our patients 
have been continuously monitored, according to 
recommendations available (1,4,17). Interestingly, 
there are a growing number of reports regarding 
the induction or exacerbation of psoriasis in pa-
tients with rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis and Crohn’s disease re-
ceiving TNF-α inhibitor therapy. This paradoxical 
side effect usually responds to conventional pso-
riasis treatment and does not necessarily require 
therapy cessation (18,19).
 The new biologic agents have significantly in-
creased therapeutic choices for the management 
of moderate-to-severe psoriasis. Apart from inflix-
imab, clinical efficacy in the treatment of psoriasis 
has been shown for two additional antagonists of 
TNF-α, adalimumab (Humira®) and etanercept 
(Enbrel®), as well as for the T cell inhibitors efalizu-
mab (Raptiva®) and alefacept (Amevive®) (1). Our 
experience is an example of great therapeutic ad-
vance achieved in patients with severe, previously 
treatment-resistant psoriasis. In Croatia, due to 
the substantial costs of such treatment modalities, 
severe psoriasis remains a therapeutic challenge. 
The use of biologic agents has thus far been re-
stricted to patients with psoriatic arthritis that have 
responded inadequately to methotrexate, like the 
ones presented in this report. 
 Note added in proof: Since submission of this 
report, both of the presented patients have been 
treated with infliximab for a total period of 78 and 
62 weeks, respectively. In Patient 1, we recently 
observed a gradual loss of clinical efficacy as her 
PASI score increased to 12.3 (56% improvement 
from baseline) before twelfth infusion. Therefore, 
we decided to shorten the interval between future 
infusions to every 6 weeks, or eventually consider 
discontinuation of therapy with this biologic agent. 
Patient 2 remained completely free of skin lesions, 
has received 10 infusions thus far and had none 
adverse effect of the treatment.
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